Neurocrine Biosciences (NBIX) Free Cash Flow Growth (1y) (2011 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.24 Bn | 623.49 Bn | 17.26 Bn | 157.32% |
| 2 | AbbVie | 443.24 Bn | 436.67 Bn | 12.70 Bn | -36.24% |
| 3 | Merck | 364.92 Bn | 357.78 Bn | 12.21 Bn | 77.03% |
| 4 | Novartis Ag | 266.33 Bn | 258.64 Bn | 11.24 Bn | -11.32% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 125.17% |
| 6 | Sanofi | 52.37 Bn | 44.99 Bn | 10.79 Bn | 107.90% |
| 7 | Revolution Medicines | 44.03 Bn | 44.03 Bn | - | - |
| 8 | Incyte | 25.35 Bn | 20.82 Bn | 1.57 Bn | 1,829.52% |
| 9 | United Therapeutics | 21.58 Bn | 18.92 Bn | 683.80 Mn | 58.76% |
| 10 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 43.69% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 43.69% |
| Mar 31, 2026 | 152.68% |
| Dec 31, 2025 | 66.16% |
| Sep 30, 2025 | 42.96% |
| Jun 30, 2025 | 68.87% |
| Mar 31, 2025 | -54.58% |
| Dec 31, 2024 | 99.15% |
| Sep 30, 2024 | -26.66% |
| Jun 30, 2024 | -69.33% |
| Mar 31, 2024 | 189.08% |
| Dec 31, 2023 | -16.36% |
| Sep 30, 2023 | 103.38% |
| Jun 30, 2023 | 33.64% |
| Mar 31, 2023 | -177.96% |
| Dec 31, 2022 | 3,104.26% |
| Sep 30, 2022 | 79.14% |
| Jun 30, 2022 | 30.74% |
| Mar 31, 2022 | -158.09% |
| Dec 31, 2021 | -105.22% |
| Sep 30, 2021 | 369.71% |